Sign up for a free trial and join thousands of other leading professionals. Click here to start!

Chronic Lymphocytic Leukemia News

Home | Index > Health > Cancer > Chronic Lymphocytic Leukemia

TAKE THIS POLL
Is Belgian Prime Minister Herman Van Rompuy the right person to lead the EU as its president? (Nov. 20, 2009) Yes. No. Don't know.

Sort by: relevance (24 hours) relevance date

High Mitochondrial DNA Stability in B-Cell Chronic Lymphocytic Leukemia 22 Nov 2009 11:55 GMT
... / High Mitochondrial DNA Stability in B-Cell Chronic Lymphocytic Leukemia High Mitochondrial DNA Stability in B-Cell Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia (CLL) leads ...
Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia 18 Nov 2009 21:36 GMT
... Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. - (BUSINESS WIRE) - Genentech, Inc., a ...
FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia 19 Nov 2009 09:16 GMT
... VeriChip Corporation, a provider of radio frequency identification (RFID) systems for healthcare and... Human Genome Sciences, Inc. and ...
BRIEF-Genentech and Biogen get FDA complete response for Rituxan in chronic lymphocytic leukemia 18 Nov 2009 22:39 GMT
... ...
Medical Edge: More effective treatments available for lymphocytic leukemia 16 Nov 2009 15:17 GMT
... effective treatments available for lymphocytic leukemia DEAR MAYO CLINIC: I was recently diagnosed with chronic lymphocytic leukemia. I am 55 years old, exercise regularly and feel fine. I have no symptoms. ...

Discovery holds promise in fighting cancer, AIDS and autoimmune disorders 21 Nov 2009 08:13 GMT
... for nearly 30 years." To identify the true FCMR gene, the UAB researchers used chronic lymphocytic leukemia cells as a source of this gene, since such leukemia cells are known to ...
Facet Biotech Announces Four Presentations at American Society of Hematology Annual Meeting 19 Nov 2009 13:50 GMT
... Small Modular Immuno-Pharmaceutical (TruADhanCe(TM) SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells. Lead Investigator: Sarwish Rafiq, MD, Ohio State University Comprehensive Cancer Center When: Saturday, ...
Facet Biotech Announces Four Presentations at American Society of Hematology 19 Nov 2009 14:15 GMT
... Small Modular Immuno-Pharmaceutical (TruADhanCe(TM) SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells. Lead Investigator: Sarwish Rafiq, MD, Ohio State University Comprehensive Cancer Center When: Saturday, ...
Dr. Mark Weiss Joins the Department of Medical Oncology at Jefferson 17 Nov 2009 02:51 GMT
... at Jefferson, as he is internationally known for his work in hematologic malignancies, particularly chronic lymphocytic leukemia and acute lymphocytic leukemia." Dr. Weiss earned his Bachelor of Arts from Cornell University ...
Go Healthy, Not Hungry for Holiday Eating 22 Nov 2009 15:12 GMT
... (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia. Twynsta (telmisartan/amlodipine) is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel ...

Not satisfied with this news section? Make your own with the Newsletter Manager or try our other media monitoring services.

Stunts Raise Injury Risks for Cheerleaders 21 Nov 2009 15:33 GMT
... (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia. Twynsta (telmisartan/amlodipine) is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel ...
When Sleep Suffers, So Does Decisiveness 21 Nov 2009 15:33 GMT
... (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia. Twynsta (telmisartan/amlodipine) is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel ...
Reuters Health: Terra med Alliance News Green Tea Ingredient May Fight Incurable Leukemia 19 Nov 2009 02:31 GMT
... tea may shrink lymph nodes and reduce white blood cell counts in patients with chronic lymphocytic leukemia (CLL), a new study in the Journal of Clinical Oncology shows. Terra med Alliance ...
Genentech, Biogen Idec Receive Complete Response from FDA for Rituxan for CLL 19 Nov 2009 13:58 GMT
... and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). Rituxan is a therapeutic antibody that binds to a specific protein called CD20 ...
Genentech, Biogen Idec get FDA request on application for Rituxan's use in leukemia 18 Nov 2009 23:37 GMT
... for new data on the current application, which seeks approval as a treatment for chronic lymphocytic leukemia. It is the most common adult leukemia in the U.S. Genentech and Biogen said ...
BUYINS.NET: Genzyme (GENZ) Daily Short Sale Trading Volume Through 11-13-09. Over 72 Million Shares Shorted in Past 3 Months. 16 Nov 2009 11:16 GMT
... products for the treatment of cancer, which include Campath for the treatment of B-cell chronic lymphocytic leukemia; Clolar for the treatment of pediatric patients 1 to 21 years old with relapsed ...
Genentech, Biogen get FDA request on Rituxan 18 Nov 2009 22:12 GMT
... for new data on the current application, which seeks approval as a treatment for chronic lymphocytic leukemia. It is the most common adult leukemia in the U.S. Genentech and Biogen said ...
Genentech and Biogen Receive FDA Letter Over Rituxan 20 Nov 2009 04:34 GMT
... for new data on the current application, which seeks approval as a treatment for chronic lymphocytic leukemia. It is the most common adult leukemia in the U.S. Genentech and Biogen said ...
FDA Clears Way for Use of Rituxan for Leukemia 20 Nov 2009 06:58 GMT
... FDA has approved Genentech and Biogen Idec's Rituxan plus chemotherapy for patients with untreated chronic lymphocytic leukemia (CLL), opening up a new market for the pharmaceutical. This article is viewable by ...
Intravenous immunoglobulin treatments made possible by the generosity of blood donors 15 Nov 2009 16:51 GMT
... use in the treatment of the following diseases and conditions: • primary immunodeficiencies • Chronic Lymphocytic Leukemia • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) • Idiopathic Thrombocytopenic Purpura • Kawasaki Disease • ...

THESE STORIES ARE NOT PUBLISHED BY IPD GROUP, INC. AND THESE LINKS WILL TAKE YOU TO OTHER WEBSITES. SOME OF THESE WEBSITES REQUIRE THEIR OWN REGISTRATION TO READ THEIR STORIES. PLEASE READ THE DISCLAIMER FOR MORE DETAILS. >>>

Lonza Successfully Develops A Manufacturing Process For Arzerra (Ofatumumab), A New Biopharmaceutical From GSK And Genmab 17 Nov 2009 06:51 GMT
... and Genmab's antibody Arzerra, which has just been approved for use in patients with chronic lymphocytic leukemia (CLL) by the US Food and Drug Administration (FDA), will be manufactured by Lonza. ...
Genetic identity of cellular receptor for the immune system's first-response antibody discovered 19 Nov 2009 11:33 GMT
... for nearly 30 years." To identify the true FCMR gene, the UAB researchers used chronic lymphocytic leukemia cells as a source of this gene, since such leukemia cells are known to ...
Celgene and Innate Collaborate on Trial Combining Their Multiple Myeloma Therapies 18 Nov 2009 16:42 GMT
... dysplastic syndrome with deletion 5q. Additionally, the drug is in Phase III trials against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma as well as Phase II development against solid tumors. ...
Researchers Discover Antibody Receptor Identity, Propose Renaming Immune-System Gene 18 Nov 2009 21:54 GMT
... for nearly 30 years." To identify the true FCMR gene, the UAB researchers used chronic lymphocytic leukemia cells as a source of this gene, since such leukemia cells are known to ...
Genentech, Biogen Get FDA Request On Rituxan 18 Nov 2009 22:14 GMT
... for new data on the current application, which seeks approval as a treatment for chronic lymphocytic leukemia. It is the most common adult leukemia in the U.S. Genentech and Biogen said ...